A Phase I/Randomized Phase II Study of Cediranib (NSC 732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma.

Trial Profile

A Phase I/Randomized Phase II Study of Cediranib (NSC 732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Cediranib (Primary) ; Cisplatin; Pemetrexed
  • Indications Mesothelioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Results of phase I part of this study (n=20) published in the Journal of Thoracic Oncology
    • 10 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
    • 17 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top